Latest Conference Articles

December 5th 2016, 11:30pm

ASH Annual Meeting and Exposition

The combination of the PI3 kinase inhibitor TGR-1202 and ibrutinib demonstrated a high response rate without dose-limiting toxicities for patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

December 5th 2016, 10:56pm

IASLC World Conference on Lung Cancer

Joshua Roth, PhD, assistant member, Fred Hutchinson Cancer Research Center, discusses the rationale behind the development of a novel risk-prediction algorithm in the context of screening patients for lung cancer. He discussed this during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

December 5th 2016, 10:27pm

IASLC World Conference on Lung Cancer

Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses the LuCED test, a non-invasive tool used to detect early stage lung cancer, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

December 5th 2016, 10:24pm

IASLC World Conference on Lung Cancer

While treatment with nivolumab (Opdivo) significantly improved overall survival over docetaxel in patients with advanced non–small cell lung cancer in the CheckMate-057 trial, an analysis of deaths occurring within 3 months of initiation of therapy showed numerically more deaths in the nivolumab arm.

December 5th 2016, 8:08pm

IASLC World Conference on Lung Cancer

Douglas Arenberg, MD, discusses preliminary findings of a screening study, and the critical importance of maintaining quality tobacco cessation practices in healthcare clinics.

December 5th 2016, 9:06am

ASH Annual Meeting and Exposition

John M. Burke, MD, discusses the GOYA study, a phase III study investigating obinutuzumab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma. Burke discussed the study during the American Society of Hematology (ASH) Annual Meeting.

December 5th 2016, 8:26am

ASH Annual Meeting and Exposition

Combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 34% versus rituximab plus chemotherapy in patients with follicular lymphoma, according to findings from the phase III GALLIUM study.

December 5th 2016, 8:24am

ASH Annual Meeting and Exposition

Treatment with the combination of pembrolizumab, pomalidomide, and dexamethasone demonstrated promising durable efficacy and a tolerable safety profile for patients with relapsed/refractory multiple myeloma.

December 5th 2016, 7:26am

ASH Annual Meeting and Exposition

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses some of the recent exciting advancements in the field of multiple myeloma during the American Society of Hematology (ASH) Annual Meeting.

December 5th 2016, 4:55am

ASH Annual Meeting and Exposition

Ibrutinib showed an 89% response rate in both treatment-naïve and relapsed patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in findings from the longest follow-up to date for the BTK inhibitor.

December 5th 2016, 3:55am

ASH Annual Meeting and Exposition

Lenalidomide as maintenance following first-line immunochemotherapy substantially improves progression-free survival in the treatment of patients with high-risk chronic lymphocytic leukemia.

December 5th 2016, 2:49am

ASH Annual Meeting and Exposition

The combination of the killer-cell immunoglobulin-like receptors inhibitor lirilumab with the hypomethylating agent azacytidine was well tolerated and showed early signals of activity in heavily pretreated patients with acute myeloid leukemia.

December 5th 2016, 2:48am

ASH Annual Meeting and Exposition

Treatment with enasidenib was active and was well tolerated in pretreated patients with IDH2-mutated myelodysplastic syndrome, including those who failed hypomethylating agents.

December 4th 2016, 11:46pm

ASH Annual Meeting and Exposition

Researchers are hopeful that the addition of the investigational agent vadastuximab talirine to standard 7+3 induction therapy may improve survival for patients with acute myeloid leukemia.

December 4th 2016, 12:18pm

ASH Annual Meeting and Exposition

The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

December 4th 2016, 9:27am

ASH Annual Meeting and Exposition

Mrinal S. Patnaik, MBBS, hematologist, Mayo Clinic, discusses a study investigating SL-401 in patients with myeloproliferative neoplasms during the American Society of Hematology (ASH) Annual Meeting.

December 4th 2016, 8:37am

ASH Annual Meeting and Exposition

Constantine Tam, MD, discusses 2 trials investigating BTK inhibitor BGB-3111 in chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia.

December 4th 2016, 6:42am

ASH Annual Meeting and Exposition

TKIs can safely be stopped or dose-reduced without jeopardizing long-term outcomes for select patients with chronic myeloid leukemia who have obtained a major molecular response.

December 4th 2016, 5:56am

ASH Annual Meeting and Exposition

Brentuximab vedotin induced responses lasting at least 4 months in 56% of patients with cutaneous T-cell lymphoma versus 13% in patients receiving physician’s choice of standard therapies, according to findings from the phase III ALCANZA trial presented at the 2016 ASH Annual Meeting.

December 4th 2016, 4:30am

ASH Annual Meeting and Exposition

CPX-351 may provide a bridge to successful transplantation for older patients with acute myeloid leukemia with limited treatment options.